Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Eitemau Tebyg

• Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
  gan: Allevi, G, et al.
  Cyhoeddwyd: (2013)
• Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
  gan: Generali, D, et al.
  Cyhoeddwyd: (2009)
• Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
  gan: Generali, D, et al.
  Cyhoeddwyd: (2008)
• Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
  gan: Generali, D, et al.
  Cyhoeddwyd: (2011)
• Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
  gan: Fox, S, et al.
  Cyhoeddwyd: (2006)